Doxorubicin selects for fluconazole-resistant petite mutants in Candida glabrata isolates

International Journal of Medical Microbiology

Volumn 302, Issue 3, 2012, Pages 155-161

  Schulz, Bettina ^a   Knobloch, Mathias ^a   Weber, Kai ^a   Ruhnke, Markus ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

ABC transporter; Candida glabrata; Doxorubicin; Fluconazole susceptibility; Petite mutants; Resistance

Indexed keywords

ABC TRANSPORTER; ACT1 PROTEIN; AGAR; CDR1 PROTEIN; CDR2 PROTEIN; DOXORUBICIN; FLUCONAZOLE; FUNGAL PROTEIN; GLYCEROL; PDR1 PROTEIN; SNQ2 PROTEIN; UNCLASSIFIED DRUG;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA GLABRATA; CARBON SOURCE; CONTROLLED STUDY; FUNGAL GENE; FUNGUS ISOLATION; GENE OVEREXPRESSION; INCUBATION TIME; LONG TERM EXPOSURE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROTEIN EXPRESSION;

ANTIFUNGAL AGENTS; CANDIDA GLABRATA; CANDIDIASIS; DOXORUBICIN; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; GENE EXPRESSION PROFILING; HUMANS; MICROBIAL SENSITIVITY TESTS; SELECTION, GENETIC;

EID: 84862311161     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2012.04.002     Document Type: Article

References (32)

1. Bouchara J.P., Zouhair R., Le B.S., Renier G., Filmon R., Chabasse D., Hallet J.N., Defontaine A. In vivo selection of an azole-resistant petite mutant of Candida glabrata. J. Med. Microbiol. 2000, 49:977-984.
2. Brun S., Aubry C., Lima O., Filmon R., Berges T., Chabasse D., Bouchara J.P. Relationships between respiration and susceptibility to azole antifungals in Candida glabrata. Antimicrob. Agents Chemother. 2003, 47:847-853.
3. Brun S., Berges T., Poupard P., Vauzelle-Moreau C., Renier G., Chabasse D., Bouchara J.P. Mechanisms of azole resistance in petite mutants of Candida glabrata. Antimicrob. Agents Chemother. 2004, 48:1788-1796.
4. Bulder C.J. Induction of petite mutation and inhibition of synthesis of respiratory enzymes in various yeasts. Anton. Van Leeuw. 1964, 30:1-9.
5. Buschini A., Poli P., Rossi C. Saccharomyces cerevisiae as an eukaryotic cell model to assess cytotoxicity and genotoxicity of three anticancer anthraquinones. Mutagenesis 2003, 18:25-36.
6. Carter S.K. Adriamycin-a review. J. Natl. Cancer Inst. 1975, 55:1265-1274.
7. Clinical Laboratory Standards Institute Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved Standard M27-A 1997, National Committee for Clinical Laboratory Standards, Wayne, PA.
8. Coleman D.C., Moran G.P., McManus B.A., Sullivan D.J. Mechanisms of antifungal drug resistance in Candida dubliniensis. Future Microbiol. 2010, 5:935-949.
9. Dougherty P.F., Yotter D.W., Matthews T.R. Microdilution transfer plate technique for determining in vitro synergy of antimicrobial agents. Antimicrob. Agents Chemother. 1977, 11:225-228.
10. Ferrari S., Sanguinetti M., De B.F., Torelli R., Posteraro B., Vandeputte P., Sanglard D. Loss of mitochondrial functions associated with azole resistance in Candida glabrata results in enhanced virulence in mice. Antimicrob. Agents Chemother. 2011, 55:1852-1860.
11. Goswami D., Goswami R., Banerjee U., Dadhwal V., Miglani S., Lattif A.A., Kochupillai N. Pattern of Candida species isolated from patients with diabetes mellitus and vulvovaginal candidiasis and their response to single dose oral fluconazole therapy. J. Infect. 2006, 52:111-117.
12. Hixon S.C., Ocak A., Thomas J.E., Daugherty J.P. Resistance to adriamycin cytotoxicity among respiratory-deficient mutants in yeast. Antimicrob. Agents Chemother. 1980, 17:443-449.
13. Kaur R., Castano I., Cormack B.P. Functional genomic analysis of fluconazole susceptibility in the pathogenic yeast Candida glabrata: roles of calcium signaling and mitochondria. Antimicrob. Agents Chemother. 2004, 48:1600-1613.
14. Kofla G., Ruhnke M. Development of a new real-time TaqMan PCR assay for quantitative analyses of Candida albicans resistance genes expression. J. Microbiol. Methods 2007, 68:178-183.
15. Kofla G., Turner V., Schulz B., Storch U., Froelich D., Rognon B., Coste A.T., Sanglard D., Ruhnke M. Doxorubicin induces drug efflux pumps in Candida albicans. Med. Mycol. 2011, 49:132-142.
16. Kule C., Ondrejickova O., Verner K. Doxorubicin, daunorubicin, and mitoxantrone cytotoxicity in yeast. Mol. Pharmacol. 1994, 46:1234-1240.
17. Nucci M., Marr K.A. Emerging fungal diseases. Clin. Infect. Dis. 2005, 41:521-526.
18. Odds F.C. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 2003, 52:1.
19. Pfaller M.A., Castanheira M., Messer S.A., Moet G.J., Jones R.N. Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009). Diagn. Microbiol. Infect. Dis. 2010, 68:278-283.
20. Pfaller M.A., Diekema D.J. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J. Clin. Microbiol. 2004, 42:4419-4431.
21. Pfaller M.A., Diekema D.J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 2007, 20:133-163.
22. Pfaller M.A., Diekema D.J., Gibbs D.L., Newell V.A., Ellis D., Tullio V., Rodloff A., Fu W., Ling T.A. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J. Clin. Microbiol. 2010, 48:1366-1377.
23. Ro D.K., Ouellet M., Paradise E.M., Burd H., Eng D., Paddon C.J., Newman J.D., Keasling J.D. Induction of multiple pleiotropic drug resistance genes in yeast engineered to produce an increased level of anti-malarial drug precursor, artemisinic acid. BMC Biotechnol. 2008, 8:83.
24. Safdar A., Chaturvedi V., Cross E.W., Park S., Bernard E.M., Armstrong D., Perlin D.S. Prospective study of Candida species in patients at a comprehensive cancer center. Antimicrob. Agents Chemother. 2001, 45:2129-2133.
25. Sanglard D., Ischer F., Bille J. Role of ATP-binding-cassette transporter genes in high-frequency acquisition of resistance to azole antifungals in Candida glabrata. Antimicrob. Agents Chemother. 2001, 45:1174-1183.
26. Sanglard D., Ischer F., Calabrese D., Majcherczyk P.A., Bille J. The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrob. Agents Chemother. 1999, 43:2753-2765.
27. Schulz B., Knobloch M., Moran G.P., Weber K., Ruhnke M. Influence of doxorubicin on fluconazole susceptibility and efflux pump gene expression of Candida dubliniensis. Med. Mycol. 2012, 50:421-426.
28. Segal B.H., Kwon-Chung J., Walsh T.J., Klein B.S., Battiwalla M., Almyroudis N.G., Holland S.M., Romani L. Immunotherapy for fungal infections. Clin. Infect. Dis. 2006, 42:507-515.
29. Thakur J.K., Arthanari H., Yang F., Pan S.J., Fan X., Breger J., Frueh D.P., Gulshan K., Li D.K., Mylonakis E., Struhl K., Moye-Rowley W.S., Cormack B.P., Wagner G., Naar A.M. A nuclear receptor-like pathway regulating multidrug resistance in fungi. Nature 2008, 452:604-609.
30. Torelli R., Posteraro B., Ferrari S., La S.M., Fadda G., Sanglard D., Sanguinetti M. The ATP-binding cassette transporter-encoding gene CgSNQ2 is contributing to the CgPDR1-dependent azole resistance of Candida glabrata. Mol. Microbiol. 2008, 68:186-201.
31. Tsai H.F., Krol A.A., Sarti K.E., Bennett J.E. Candida glabrata PDR1, a transcriptional regulator of a pleiotropic drug resistance network, mediates azole resistance in clinical isolates and petite mutants. Antimicrob. Agents Chemother. 2006, 50:1384-1392.
32. Westermeyer C., Macreadie I.G. Simvastatin reduces ergosterol levels, inhibits growth and causes loss of mtDNA in Candida glabrata. FEMS Yeast Res. 2007, 7:436-441.